{"name":"BioLife Solutions","slug":"biolife","ticker":"BLFS","exchange":"NASDAQ","domain":"biolifesolutions.com","description":"BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines;  and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-conne","hq":"Bothell, WA","founded":0,"employees":"155","ceo":"Rod de Greef","sector":"Life Sciences Tools","stockPrice":19.69,"stockChange":0.56,"stockChangePercent":2.93,"marketCap":"$951M","metrics":{"revenue":200000000,"revenueGrowth":63.9,"grossMargin":64.6,"rdSpend":7566000,"netIncome":-4595000,"cash":88927000,"dividendYield":0,"peRatio":67.9,"fiscalYear":"FY2014"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-22","type":"earnings","headline":"BioLife Solutions Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"BioLife Solutions reported its financial results for the fourth quarter and full year 2022, with revenue increasing 24% year-over-year.","drugName":"","sentiment":"positive"},{"date":"2022-09-01","type":"deal","headline":"BioLife Solutions Announces Collaboration with Leading Biotechnology Company","summary":"BioLife Solutions announced a collaboration with a leading biotechnology company to support the development of cell and gene therapies.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-04","type":"earnings","source":"simplywall.st","summary":"A Look At BioLife Solutions (BLFS) Valuation After Earnings Beat And 2026 Growth Guidance - simplywall.st","headline":"A Look At BioLife Solutions (BLFS) Valuation After Earnings Beat And 2026 Growth Guidance","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-03-02","type":"earnings","source":"simplywall.st","summary":"Does BioLife’s 2026 Profitability Guidance and Media Strength Change The Bull Case For BLFS? - simplywall.st","headline":"Does BioLife’s 2026 Profitability Guidance and Media Strength Change The Bull Case For BLFS?","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-19","type":"pipeline","source":"simplywall.st","summary":"Is There Still Opportunity in BioLife Solutions After 15% Share Price Gain in 2025? - simplywall.st","headline":"Is There Still Opportunity in BioLife Solutions After 15% Share Price Gain in 2025?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-06","type":"pipeline","source":"simplywall.st","summary":"BioLife Solutions, Inc.'s (NASDAQ:BLFS) P/S Is Still On The Mark Following 25% Share Price Bounce - simplywall.st","headline":"BioLife Solutions, Inc.'s (NASDAQ:BLFS) P/S Is Still On The Mark Following 25% Share Price Bounce","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-09","type":"pipeline","source":"simplywall.st","summary":"Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment? - simplywall.st","headline":"Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE54bDY5c2d1UFY0dXU2anNlX24wbkZzdWpRVU5FZFl1VktqWk1EOVJ4bk03Zk5JR3NuUkwwb2pMVmZtNHk1blV2YXI1WlozOFdD?oc=5","date":"2024-02-11","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxObmlJLWowUjNaMTN6aWlFcmkxbjFLSVM2M2VfM3F6VEs3NkFLUWRpM0tRYXR1cW96ekFoV014OXptVjg2TmhOSXN2TUtDOWN4ZjNoYS1PSVJSYjBGaWRuWFE1SW9ZZ01yQXgtOGNZVFM2QXV6d3J6MWJuWFFDSFJBWFpVUXpGa1FJRWNLUzVNZmNwYzVJVmtmeFNSc0o1blBNdm9DM0RiSVktVEFDQm91aFlaNmFSVFk1RXJRTnFEbm5yZF84X3hEUHp1LW0wcUFjWDBCU0ZFWm9QRXpsRExNZnlUcHZsRTJRRmp0anRFdkNlLUwwUXFFMmZn?oc=5","date":"2022-10-12","type":"deal","source":"BioPharma APAC","summary":"CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platform - BioPharma APAC","headline":"CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platf","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1ELU5SRkZhSXktbHd3a3hwaWdKb2t2b0FDcnNXM3FncmNKUUVpTHl0RzdxOUdQclRHWHB1R3QyQndiZkZ3RlNKUkRWamZQV2I1b3kweGxSakFzejRUS2paOGlhbmRwU0VNS3d0V3BBNENBWkkyQVAtX0VFSQ?oc=5","date":"2022-09-20","type":"pipeline","source":"Nanalyze","summary":"Cold Chain Logistics Stocks: BioLife vs Cryoport - Nanalyze","headline":"Cold Chain Logistics Stocks: BioLife vs Cryoport","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNTnpqdzB0TkRKSno1UTdrZ3E0R2dqcWh3WGtTRDlxcVdnamRON1Q0YWRaSFdXNUJnYUFfSUFjZG8wN0dNMEdiSXN5cnh6eW5WaER3RG1xWVBZOVFONGdoSWZKZGlGZmNWRU9ldGcwZHBrNkt2TjJBQlBwZjgtdnFINFVrQ3ktYlRqMS0td09qd2VoQnVlVHUtMzl5dFR0Q1RDajc5TGsxTVZleFB5c0NSbnNuT2lSZlFuQUp1MTRVZmNRbTNOSUtMeXVGbzg2aE9ieXdUWmFOVDZTQ3VVdHJVVGRpc0NwaHNuYXlxSU8zUTRoQklXX1RLLTNuaG5VbGZFQkE?oc=5","date":"2020-09-21","type":"deal","source":"PR Newswire","summary":"BioLife Solutions to Acquire SciSafe, a High-Growth Biostorage Service Provider to the Cell and Gene Therapy Industry - PR Newswire","headline":"BioLife Solutions to Acquire SciSafe, a High-Growth Biostorage Service Provider to the Cell and Gene Therapy Industry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9aMTVoR0VwVEQ1a1dHUjAtRHFuYkhOX0c4WFFOMk5Dc00yMnFLdVNSTGt5LUhHVlk1d3JfbmlZWjZZSm1tcDNJMmRyQUtjV1dUaW1kT0pxSFFXSlhBM19taTEwSVREbEJTaXppOW1R0gFzQVVfeXFMUExOYzVhcjJXUzlaTEc5eXI1ZFFQYjd3UTd3Y1Z1ZE9vQnZfd0N5MnNHYkFEbVN3Q0hUNkU2enJhNkY3aUNYRFJLUC1iajU4aGlPeUV6Tk93Y3hXNzFhQmxza1lYelU2c20yVmFOSzlSSm9hSQ?oc=5","date":"2017-10-19","type":"regulatory","source":"BioInformant","summary":"BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ CAR T-Cell Therapy - BioInformant","headline":"BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ CAR T-Cell Therapy","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Thermo Fisher Scientific","Corning Incorporated","Sartorius AG"],"therapeuticFocus":["Cell and Gene Therapy","Regenerative Medicine"],"financials":{"source":"sec_edgar+yahoo","revenue":6190698,"revenuePeriod":"2014-12-31","revenueHistory":[{"value":6190698,"period":"2014-12-31"},{"value":8949401,"period":"2013-12-31"},{"value":8949401,"period":"2013-12-31"},{"value":5662990,"period":"2012-12-31"},{"value":5662990,"period":"2012-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":7566000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-4595000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":405884000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":155,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":19.69,"previousClose":19.13,"fiftyTwoWeekHigh":29.62,"fiftyTwoWeekLow":17.86,"fiftyTwoWeekRange":"17.86 - 29.62","fiftyDayAverage":21.16,"twoHundredDayAverage":23.86,"beta":2,"enterpriseValue":852948992,"forwardPE":67.9,"priceToBook":2.55,"priceToSales":9.88,"enterpriseToRevenue":8.87,"enterpriseToEbitda":236.54,"pegRatio":0,"ebitda":3606000,"ebitdaMargin":3.7,"freeCashflow":12438375,"operatingCashflow":20115000,"totalDebt":17897000,"debtToEquity":4.8,"currentRatio":5.94,"returnOnAssets":-0.2,"returnOnEquity":-3.4,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":10,"targetMeanPrice":32.4,"targetHighPrice":34,"targetLowPrice":30,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.6,"institutionHeldPercent":106.4,"sharesOutstanding":48300000,"floatShares":40528047,"sharesShort":3101825,"shortRatio":6.24,"shortPercentOfFloat":6.4,"epsTrailing":-0.25,"epsForward":0.29,"revenuePerShare":2.02,"bookValue":7.72,"officers":[{"age":65,"name":"Mr. Roderick  de Greef","title":"CEO & Chairman"},{"age":40,"name":"Mr. Troy  Wichterman CPA","title":"Chief Financial Officer"},{"age":53,"name":"Dr. Aby J. Mathew Ph.D.","title":"Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer"},{"age":56,"name":"Mr. Todd  Berard","title":"Chief Commercial Officer"},{"age":50,"name":"Mr. Sean  Werner Ph.D.","title":"Chief Technology Officer"},{"age":49,"name":"Ms. Sarah  Aebersold J.D.","title":"Chief Human Resources Officer"}],"industry":"Medical Instruments & Supplies","irWebsite":"","website":"https://www.biolifesolutions.com","phone":"425 402 1400"}}